Fresh Tracks Therapeutics (FRTX) 10-Q2022 Q1 Quarterly report

Filed: 12 May 22, 4:12pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: accomplishment, AD, adjourn, adjourned, administered, admission, advocacy, agenda, Alzheimer, Andrew, appeal, approach, ascending, autoinflammatory, baby, bacteria, Botanix, boxed, brain, Carna, cellular, center, cGAMP, Chief, Chinese, clarify, CLK, coal, commodity, Compensatory, conflict, contractor, convenience, Cooperation, Counsel, covalent, cyclic, cytokine, David, defective, defense, Departure, detecting, dramatically, DYRK, earnout, EMA, escalation, experimental, faster, float, freight, gas, genetic, geopolitical, image, IND, ingredient, instability, Interbank, interferon, invading, invasion, justified, led, length, levied, library, licensee, linked, liquified, lockdown, lost, MAD, magnify, McAvoy, MDT, mediator, messenger, mice, military, molecule, Monopolar, mutual, notification, oil, oncology, orphan, overproduction, palmitoylation, Panel, Parkinson, PCT, peripherally, pharmacology, proof, proxy, quorum, rare, Russia, Russian, SAD, sensor, Shanghai, Sklawer, Society, solicit, spindle, step, stimulation, Stimulator, STING, stringent, superior, suppressing, Syndrome, synthase, Treaty, TSA, TTK, turn, Ukraine, underway, unmet, vendor, vitro

Removed: absorbed, acetylcholine, activating, adult, Africa, aged, Allergan, amendment, ancillary, API, ASC, Australia, average, axillae, baseline, bedtime, block, body, BOTOX, Cardigan, category, cholinergic, cloth, Codification, compounded, comprised, conform, controlling, crystalline, curettage, dermal, dermatologic, dermatological, destroy, discontinued, disfavor, dosage, driven, earn, East, economical, endoscopic, estimated, excision, exercising, exert, FASB, forced, frame, glycopyrronium, gravimetric, GSP, hindered, improvement, Incorporated, increasing, initiated, intradermal, involving, Japanese, line, liposuction, locally, managed, marked, marketable, medicine, metabolized, Middle, MiraDry, Miramar, multicenter, newly, observed, older, original, originally, OTC, overactive, overcoming, payor, pediatric, physiologically, played, plc, PMDA, policy, polymorphic, positive, prescribing, prevalence, proper, proportion, prospective, purpose, Qbrexza, ratio, referred, refill, reimburse, rest, Retrometabolic, retrometabolically, run, salesforce, scrutiny, seeking, skin, sophisticated, statistical, stricter, substance, surface, Surgical, sweat, sweating, sympathectomy, thermoregulation, thoracic, tied, Topic, topical, topically, unacceptably, Unaudited, underarm, unexpected, uniform, unvested, update, usage, validated, vehicle, vision, vital, weakening, weighted, winding, worth

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated FRTX transcripts

FRTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

SECTION 1350 CERTIFICATION

Each of the undersigned, Robert. B. Brown, Chief Executive Officer of Brickell Biotech, Inc., a Delaware corporation (the “Company”), and Albert N. Marchio, II, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge (1) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




									/s/ Robert. B. Brown
									Robert B. Brown
									Chief Executive Officer (Principal Executive Officer)
									Date: May 12, 2022

									/s/ Albert N. Marchio, II
									Albert N. Marchio, II
									Chief Financial Officer (Principal Financial Officer)
									Date: May 12, 2022

This certification accompanies and is being “furnished” with this Report, shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.